IV iron drugs market seen reaching $6.6 billion by 2032

Persistence Market Research says the global intravenous iron drugs market will grow from $3.7 billion in 2025 to $6.6 billion by 2032, driven by rising iron deficiency anemia, chronic disease care and broader use of infusion therapies. Hospitals lead current demand, while North America remains the top regional market.

Why it matters: - Intravenous iron drugs are gaining traction as doctors look for faster ways to treat iron deficiency and iron deficiency anemia when oral supplements do not work. - Demand is rising across chronic kidney disease, gastrointestinal disorders, cancer-related anemia and other conditions that limit iron absorption. - The market forecast points to more spending on infusion therapies, hospital services and advanced anemia treatment.

What happened: - Persistence Market Research projects the global intravenous (IV) iron drugs market will rise from US$3.7 billion in 2025 to US$6.6 billion by 2032. - The report pegs the market at an 8.7% CAGR from 2025 to 2032. - The update was published July 8, 2026 from Brenford, London, United Kingdom. - The report says hospitals remain the leading end user, and North America leads the market regionally.

The details: - The market is segmented by product type, application and end user. - IV iron therapies are used for chronic diseases, pregnancy-related anemia, surgical blood loss and gastrointestinal disorders where oral supplements are ineffective. - Modern formulations are designed to improve treatment effectiveness while minimizing adverse reactions. - Advanced IV iron products are intended to provide faster iron replenishment, better patient convenience and shorter infusion times. - Hospitals account for the largest share because they offer infusion facilities and specialist care. - Specialty clinics and ambulatory infusion centers are seeing rising demand as outpatient treatment grows. - North America benefits from advanced healthcare infrastructure, higher awareness of anemia management and supportive reimbursement policies. - Europe is growing on higher healthcare spending and an aging population. - Asia Pacific is emerging as a growth market due to improving healthcare infrastructure, rising diagnosis rates and broader access to specialty treatments.

Between the lines: - The report points to a shift toward evidence-based anemia management and away from oral-only treatment when patients cannot tolerate or absorb iron well. - Product innovation is a major theme, with pharmaceutical companies competing on safety, convenience and infusion speed. - The cost of IV therapy remains a hurdle because it requires trained staff and infusion facilities, which can limit access in lower-resource systems. - Regulatory approvals, safety monitoring and reimbursement pressure could slow launches and compress margins.

What's next: - Growth is likely to continue as diagnosis rates improve and more patients are directed to infusion-based care. - Outpatient infusion services could expand further as health systems look to reduce hospital stays and improve convenience. - Emerging economies may become a bigger source of demand as governments invest in healthcare infrastructure and specialty medicine access. - Ongoing research and new product development are expected to shape the next phase of competition.

The bottom line: - IV iron drugs are moving from a niche therapy to a broader anemia treatment option, and Persistence Market Research sees that shift driving steady global growth through 2032.